Poolbeg is renowned for its thorough research efforts, with a team experienced in launching similar businesses on the Nasdaq stock exchange. The company has appointed Shore Capital as its joint brokers, leveraging their expertise in biopharmaceutical listings on the U.S. stock exchange. The U.S. market is crucial for Poolbeg, not only for additional capital but also due to the presence of the FDA, which plays a key role in clinical trials and fast-tracking treatment commercialisation. The Behçet’s Disease candidate already has FDA Fast Track designation.
Additionally, POLB 001 has made progress in the U.S. with an Immunomodulator II patent grant, which strengthens the company’s intellectual property portfolio for partnering. According to Dr Skillington, POLB 001 shows immense promise in a $10 billion market, with data generation being equally important to protecting the company’s innovations.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
